Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012 (2012), Article ID 823902, 16 pages
http://dx.doi.org/10.1155/2012/823902
Review Article

Reactive Oxygen Species and Inhibitors of Inflammatory Enzymes, NADPH Oxidase, and iNOS in Experimental Models of Parkinson’s Disease

Department of Biotechnology, Research Institute of Inflammatory Diseases, Konkuk University, Chungju 380-701, Republic of Korea

Received 3 November 2011; Revised 23 December 2011; Accepted 9 January 2012

Academic Editor: Luc Vallières

Copyright © 2012 Sushruta Koppula et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Reynolds, C. Laurie, R. Lee Mosley, and H. E. Gendelman, “Oxidative stress and the pathogenesis of neurodegenerative disorders,” International Review of Neurobiology, vol. 82, pp. 297–325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Nunomura, G. Perry, M. A. Pappolla et al., “RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease,” Journal of Neuroscience, vol. 19, no. 6, pp. 1959–1964, 1999. View at Google Scholar · View at Scopus
  3. K. J. Barnham, C. L. Masters, and A. I. Bush, “Neurodegenerative diseases and oxidatives stress,” Nature Reviews Drug Discovery, vol. 3, no. 3, pp. 205–214, 2004. View at Google Scholar · View at Scopus
  4. J. Emerit, M. Edeas, and F. Bricaire, “Neurodegenerative diseases and oxidative stress,” Biomedicine and Pharmacotherapy, vol. 58, no. 1, pp. 39–46, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Inoue, E. F. Sato, M. Nishikawa et al., “Mitochondrial generation of reactive oxygen species and its role in aerobic life,” Current Medicinal Chemistry, vol. 10, no. 23, pp. 2495–2505, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. B. M. Babior, “NADPH oxidase,” Current Opinion in Immunology, vol. 16, no. 1, pp. 42–47, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. K. K. Griendling, D. Sorescu, and M. Ushio-Fukai, “NAD(P)H oxidase: role in cardiovascular biology and disease,” Circulation Research, vol. 86, no. 5, pp. 494–501, 2000. View at Google Scholar · View at Scopus
  8. G. Groeger, C. Quiney, and T. G. Cotter, “Hydrogen peroxide as a cell-survival signaling molecule,” Antioxidants and Redox Signaling, vol. 11, no. 11, pp. 2655–2671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Pelicano, D. Carney, and P. Huang, “ROS stress in cancer cells and therapeutic implications,” Drug Resistance Updates, vol. 7, no. 2, pp. 97–110, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. E. Thomas and B. Kalyanaraman, Oxygen Radicals and the Disease Process, Hardwood Academic Publishers, 1997.
  12. B. Halliwell and J. M. C. Gutteridge, “Role of free radicals and catalytic metal ions in human disease: an overview,” Methods in Enzymology, vol. 186, pp. 1–85, 1990. View at Publisher · View at Google Scholar · View at Scopus
  13. D. C. Wu, P. Teismann, K. Tieu et al., “NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 6145–6150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. G. T. Liberatore, V. Jackson-Lewis, S. Vukosavic et al., “Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease,” Nature Medicine, vol. 5, no. 12, pp. 1403–1409, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Hunot, F. Boissière, B. Faucheux et al., “Nitric oxide synthase and neuronal vulnerability in Parkinson's disease,” Neuroscience, vol. 72, no. 2, pp. 355–363, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Przedborski and H. Ischiropoulos, “Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease,” Antioxidants and Redox Signaling, vol. 7, no. 5-6, pp. 685–693, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. A. H. V. Schapira, “Pathogenesis of Parkinson's disease,” Bailliere's Clinical Neurology, vol. 6, no. 1, pp. 15–36, 1997. View at Google Scholar · View at Scopus
  18. Z. I. Alam, S. E. Daniel, A. J. Lees, D. C. Marsden, P. Jenner, and B. Halliwell, “A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease,” Journal of Neurochemistry, vol. 69, no. 3, pp. 1326–1329, 1997. View at Google Scholar · View at Scopus
  19. J. B. Schulz and M. F. Beal, “Mitochondrial dysfunction in movement disorders,” Current Opinion in Neurology, vol. 7, no. 4, pp. 333–339, 1994. View at Google Scholar · View at Scopus
  20. A. Slivka and G. Cohen, “Hydroxyl radical attack on dopamine,” Journal of Biological Chemistry, vol. 260, no. 29, pp. 15466–15472, 1985. View at Google Scholar · View at Scopus
  21. J. T. Greenamyre and T. G. Hastings, “Parkinsons—divergent causes convergent mechanisms,” Science, vol. 304, no. 5674, pp. 1120–1122, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Ischiropoulos and J. S. Beckman, “Oxidative stress and nitration in neurodegeneration: cause, effect, or association?” Journal of Clinical Investigation, vol. 111, no. 2, pp. 163–169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Jenner, “Oxidative stress in Parkinson's disease,” Annals of Neurology, vol. 53, supplement 3, pp. S26–S38, 2003. View at Publisher · View at Google Scholar
  24. A. G. Kanthasamy, M. Kitazawa, A. Kanthasamy, and V. Anantharam, “Role of proteolytic activation of protein Kinase Cδ in oxidative stress-induced apoptosis,” Antioxidants and Redox Signaling, vol. 5, no. 5, pp. 609–620, 2003. View at Google Scholar · View at Scopus
  25. E. Koutsilieri, C. Scheller, E. Grünblatt, K. Nara, J. Li, and P. Riederer, “Free radicals in Parkinson's disease,” Journal of Neurology, vol. 249, no. 2, supplement 2, pp. II1–II5, 2002. View at Google Scholar
  26. R. Love, “Mitochondria back in the spotlight in Parkinson's disease,” Lancet Neurology, vol. 3, no. 6, p. 326, 2004. View at Google Scholar · View at Scopus
  27. T. M. Tikka, N. E. Vartiainen, G. Goldsteins et al., “Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease,” Brain, vol. 125, no. 4, pp. 722–731, 2002. View at Google Scholar · View at Scopus
  28. J. K. Andersen, “Iron dysregulation and Parkinson's disease,” Journal of Alzheimer's Disease, vol. 6, pp. S47–S52, 2004. View at Google Scholar · View at Scopus
  29. C. Mancuso, G. Scapagnini, D. Currò et al., “Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders,” Frontiers in Bioscience, vol. 12, no. 3, pp. 1107–1123, 2007. View at Publisher · View at Google Scholar
  30. S. Mandel, G. Maor, and M. B. H. Youdim, “Iron and α-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate,” Journal of Molecular Neuroscience, vol. 24, no. 3, pp. 401–416, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. B. H. Youdim, G. Stephenson, and D. B. Shachar, “Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28,” Annals of the New York Academy of Sciences, vol. 1012, pp. 306–325, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. J. L. Venero, M. A. Burguillos, P. Brundin, and B. Joseph, “The executioners sing a new song: killer caspases activate microglia,” Cell Death and Differentiation, vol. 18, no. 11, pp. 1679–1691, 2011. View at Publisher · View at Google Scholar
  33. D. W. Dickson, S. C. Lee, L. A. Mattiace, S. H. Yen, and C. Brosnan, “Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease,” Glia, vol. 7, no. 1, pp. 75–83, 1993. View at Google Scholar · View at Scopus
  34. P. L. McGeer, S. Itagaki, B. E. Boyes, and E. G. McGeer, “Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains,” Neurology, vol. 38, no. 8, pp. 1285–1291, 1988. View at Google Scholar · View at Scopus
  35. C. S. Raine, “Multiple sclerosis: immune system molecule expression in the central nervous system,” Journal of Neuropathology and Experimental Neurology, vol. 53, no. 4, pp. 328–337, 1994. View at Google Scholar · View at Scopus
  36. J. Rogers, J. Luber-Narod, S. D. Styren, and W. H. Civin, “Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease,” Neurobiology of Aging, vol. 9, no. 4, pp. 339–349, 1988. View at Google Scholar · View at Scopus
  37. C. Knott, G. Stern, and G. P. Wilkin, “Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2,” Molecular and Cellular Neuroscience, vol. 16, no. 6, pp. 724–739, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. D. K. Choi, S. Pennathur, C. Perier et al., “Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice,” Journal of Neuroscience, vol. 25, no. 28, pp. 6594–6600, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Van Leyen, K. Arai, G. Jin et al., “Novel lipoxygenase inhibitors as neuroprotective reagents,” Journal of Neuroscience Research, vol. 86, no. 4, pp. 904–909, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. C. K. Glass, K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage, “Mechanisms Underlying Inflammation in Neurodegeneration,” Cell, vol. 140, no. 6, pp. 918–934, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. R. M. Ransohoff and V. H. Perry, “Microglial physiology: unique stimuli, specialized responses,” Annual Review of Immunology, vol. 27, pp. 119–145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Chen, “Nonsteroidal antiinflammatory drugs and the risk of Parkinson’s disease,” Movement Disorder, vol. 17, pp. S143–S144, 2002. View at Google Scholar
  43. P. L. McGeer and E. G. McGeer, “Inflammatory processes in amyotrophic lateral sclerosis,” Muscle and Nerve, vol. 26, no. 4, pp. 459–470, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. B. M. Babior, “NADPH oxidase: an update,” Blood, vol. 93, no. 5, pp. 1464–1476, 1999. View at Google Scholar · View at Scopus
  45. M. Sawada, K. Imamura, and T. Nagatsu, “Role of cytokines in inflammatory process in Parkinson's disease,” Journal of Neural Transmission, Supplement, no. 70, pp. 373–381, 2006. View at Google Scholar · View at Scopus
  46. F. Serrano, N. S. Kolluri, F. B. Wientjes, J. P. Card, and E. Klann, “NADPH oxidase immunoreactivity in the mouse brain,” Brain Research, vol. 988, no. 1-2, pp. 193–198, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Ushio-Fukai, “Localizing NADPH oxidase-derived ROS,” Science's STKE, vol. 2006, no. 349, p. re8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. D. W. Infanger, R. V. Sharma, and R. L. Davisson, “NADPH oxidases of the brain: distribution, regulation, and function,” Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1583–1596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. B. J. Tabner, S. Turnbull, O. El-Agnaf, and D. Allsop, “Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases,” Current Topics in Medicinal Chemistry, vol. 1, no. 6, pp. 507–517, 2001. View at Google Scholar · View at Scopus
  50. W. Zhang, T. Wang, Z. Pei et al., “Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease,” FASEB Journal, vol. 19, no. 6, pp. 533–542, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. M. P. Thomas, K. Chartrand, A. Reynolds, V. Vitvitsky, R. Banerjee, and H. E. Gendelman, “Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease,” Journal of Neurochemistry, vol. 100, no. 2, pp. 503–519, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Tolando, A. Jovanović, R. Brigelius-Flohé, F. Ursini, and M. Maiorino, “Reactive oxygen species and proinflammatory cytokine signaling in endothelial cells: effect of selenium supplementation,” Free Radical Biology and Medicine, vol. 28, no. 6, pp. 979–986, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Sundaresan, Z. X. Yu, V. J. Ferrans, K. Irani, and T. Finkel, “Requirement for generation of H2O2 for platelet-derived growth factor signal transduction,” Science, vol. 270, no. 5234, pp. 296–299, 1995. View at Google Scholar · View at Scopus
  54. K. Suzukawa, K. Miura, J. Mitsushita et al., “Nerve growth factor-induced neuronal differentiation requires generation of Rac1-regulated reactive oxygen species,” Journal of Biological Chemistry, vol. 275, no. 18, pp. 13175–13178, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. H. M. Gao, B. Liu, and J. S. Hong, “Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons,” Journal of Neuroscience, vol. 23, no. 15, pp. 6181–6187, 2003. View at Google Scholar · View at Scopus
  56. M. L. Block, X. Wu, Z. Pei et al., “Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase,” FASEB Journal, vol. 18, no. 13, pp. 1618–1620, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Qin, Y. Liu, C. Cooper, B. Liu, B. Wilson, and J. S. Hong, “Microglia enhance β-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species,” Journal of Neurochemistry, vol. 83, no. 4, pp. 973–983, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. X. F. Wu, M. L. Block, W. Zhang et al., “The role of microglia in paraquat-induced dopaminergic neurotoxicity,” Antioxidants and Redox Signaling, vol. 7, no. 5-6, pp. 654–661, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. H. M. Gao, J. S. Hong, W. Zhang, and B. Liu, “Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease,” Journal of Neuroscience, vol. 23, no. 4, pp. 1228–1236, 2003. View at Google Scholar · View at Scopus
  60. S. P. Green, B. Cairns, J. Rae et al., “Induction of gp91-phox, a component of the phagocyte NADPH oxidase, in microglial cells during central nervous system inflammation,” Journal of Cerebral Blood Flow and Metabolism, vol. 21, no. 4, pp. 374–384, 2001. View at Google Scholar · View at Scopus
  61. V. Anantharam, S. Kaul, C. Song, A. Kanthasamy, and A. G. Kanthasamy, “Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells,” NeuroToxicology, vol. 28, no. 5, pp. 988–997, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Qin, Y. Liu, T. Wang et al., “NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia,” Journal of Biological Chemistry, vol. 279, no. 2, pp. 1415–1421, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. S. H. Huh, Y. C. Chung, Y. Piao et al., “Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease,” Journal of Immunology, vol. 187, no. 2, pp. 960–969, 2011. View at Publisher · View at Google Scholar
  64. Q. Wang, K. D. Tompkins, A. Simonyi, R. J. Korthuis, A. Y. Sun, and G. Y. Sun, “Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus,” Brain Research, vol. 1090, no. 1, pp. 182–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. W. Lo, T. Bravo, V. Jadhav, E. Titova, J. H. Zhang, and J. Tang, “NADPH oxidase inhibition improves neurological outcomes in surgically-induced brain injury,” Neuroscience Letters, vol. 414, no. 3, pp. 228–232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. M. E. Lull, S. Levesque, M. J. Surace, and M. L. Block, “Chronic apocynin treatment attenuates beta amyloid plaque size and microglial number in hAPP(751) SL mice,” PLoS One, vol. 6, no. 5, article e20153, 2011. View at Publisher · View at Google Scholar
  67. X. N. Tang, B. Cairns, N. Cairns, and M. A. Yenari, “Apocynin improves outcome in experimental stroke with a narrow dose range,” Neuroscience, vol. 154, no. 2, pp. 556–562, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Titova, R. P. Ostrowski, L. C. Sowers, J. H. Zhang, and J. Tang, “Effects of apocynin and ethanol on intracerebral haemorrhage-induced brain injury in rats,” Clinical and Experimental Pharmacology and Physiology, vol. 34, no. 9, pp. 845–850, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. R. L. Miller, G. Y. Sun, and A. Y. Sun, “Cytotoxicity of paraquat in microglial cells: involvement of PKCδ- and ERK1/2-dependent NADPH oxidase,” Brain Research, vol. 1167, no. 1, pp. 129–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Qian, Z. Xu, W. Zhang, B. Wilson, J. S. Hong, and P. M. Flood, “Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase,” Journal of Neuroinflammation, vol. 4, article no. 23, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Ma and J. Zhou, “Dopamine promotes the survival of embryonic striatal cells: involvement of superoxide and endogenous NADPH oxidase,” Neurochemical Research, vol. 31, no. 4, pp. 463–471, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Nikolova, Y. S. Lee, Y. S. Lee, and J. A. Kim, “Rac1-NADPH oxidase-regulated generation of reactive oxygen species mediates glutamate-induced apoptosis in SH-SY5Y human neuroblastoma cells,” Free Radical Research, vol. 39, no. 12, pp. 1295–1304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. M. G. Purisai, A. L. McCormack, S. Cumine, J. Li, M. Z. Isla, and D. A. Di Monte, “Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration,” Neurobiology of Disease, vol. 25, no. 2, pp. 392–400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Yasuhara, T. Shingo, K. Kobayashi et al., “Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease,” European Journal of Neuroscience, vol. 19, no. 6, pp. 1494–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. E. C. Hirsch, T. Breidert, E. Rousselet, S. Hunot, A. Hartmann, and P. P. Michel, “The role of glial reaction and inflammation in Parkinson's disease,” Annals of the New York Academy of Sciences, vol. 991, pp. 214–228, 2003. View at Google Scholar · View at Scopus
  76. H. M. Gao, F. Zhang, H. Zhou, W. Kam, B. Wilson, and J. -S. Hong, “Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease,” Environmental Health Perspectives, vol. 119, no. 6, pp. 807–814, 2011. View at Publisher · View at Google Scholar
  77. Y. Liu, L. Qin, G. Li et al., “Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 1, pp. 212–218, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. G. Li, Y. Liu, N. S. Tzeng et al., “Protective effect of dextromethorphan against endotoxic shock in mice,” Biochemical Pharmacology, vol. 69, no. 2, pp. 233–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. W. Zhang, T. Wang, L. Qin et al., “Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase,” The FASEB Journal, vol. 18, no. 3, pp. 589–591, 2004. View at Google Scholar · View at Scopus
  80. M. Ramanathan, S. Sivakumar, P. R. Anandvijayakumar, C. Saravanababu, and P. R. Pandian, “Neuroprotective evaluation of standardized extract of centella asciatica in monosodium glutamate treated rats,” Indian Journal of Experimental Biology, vol. 45, no. 5, pp. 425–431, 2007. View at Google Scholar · View at Scopus
  81. Y. Huo, P. Rangarajan, E. A. Ling, and S. T. Dheen, “Dexamethasone inhibits the Nox-dependent ROS production via suppression of MKP-1-dependent MAPK pathways in activated microglia,” BMC Neuroscience, vol. 12, article 49, 2011. View at Publisher · View at Google Scholar
  82. W. Zhang, E. J. Shin, T. Wang et al., “3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro,” FASEB Journal, vol. 20, no. 14, pp. 2496–2511, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. F. Zhang, J. S. Shi, H. Zhou, B. Wilson, J. S. Hong, and H. M. Gao, “Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions,” Molecular Pharmacology, vol. 78, no. 3, pp. 466–477, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. R. Li, Y. G. Huang, D. Fang, and W. D. Le, “(-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury,” Journal of Neuroscience Research, vol. 78, no. 5, pp. 723–731, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Wang, S. Xu, X. Xu, and P. Chan, “(-)-epigallocatechin-3-gallate protects SH-SY5Y cells against 6-OHDA-induced cell death through stat3 activation,” Journal of Alzheimer's Disease, vol. 17, no. 2, pp. 295–304, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Ruan, Y. Yang, X. Zhu, X. Wang, and R. Chen, “Neuroprotective effects of (±)-catechin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice,” Neuroscience Letters, vol. 450, no. 2, pp. 152–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Arimura, “Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems,” Japanese Journal of Physiology, vol. 48, no. 5, pp. 301–331, 1998. View at Google Scholar · View at Scopus
  88. A. Arimura, A. Somogyvari-Vigh, C. Weill et al., “PACAP functions as a neurotrophic factor,” Annals of the New York Academy of Sciences, vol. 739, pp. 228–243, 1994. View at Google Scholar · View at Scopus
  89. T. Kozicz, S. Vigh, and A. Arimura, “Axon terminals containing PACAP- and VIP-immunoreactivity form synapses with CRF-immunoreactive neurons in the dorsolateral division of the bed nucleus of the stria terminalis in the rat,” Brain Research, vol. 767, no. 1, pp. 109–119, 1997. View at Publisher · View at Google Scholar · View at Scopus
  90. D. E. Brenneman, J. M. Hauser, C. Y. Spong, and T. M. Phillips, “Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity,” Neuropeptides, vol. 36, no. 4, pp. 271–280, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. D. Uchida, A. Arimura, A. Somogyvári-Vigh, S. Shioda, and W. A. Banks, “Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide,” Brain Research, vol. 736, no. 1-2, pp. 280–286, 1996. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Yang, J. Yang, Z. Yang et al., “Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 2, pp. 595–603, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. Q. G. Zhang, L. Raz, R. Wang et al., “Estrogen attenuates ischemic oxidative damage via an estrogen receptor α-mediated inhibition of NADPH oxidase activation,” Journal of Neuroscience, vol. 29, no. 44, pp. 13823–13836, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. K. M. Dhandapani and D. W. Brann, “Role of astrocytes in estrogen-mediated neuroprotection,” Experimental Gerontology, vol. 42, no. 1-2, pp. 70–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. J. H. M. Prehn, V. P. Bindokas, C. J. Marcuccilli, S. Krajewski, J. C. Reed, and R. J. Miller, “Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type β confers wide-ranging protection on rat hippocampal neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 26, pp. 12599–12603, 1994. View at Publisher · View at Google Scholar · View at Scopus
  96. L. Qian and P. M. Flood, “Microglial cells and Parkinson's disease,” Immunologic Research, vol. 41, no. 3, pp. 155–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Zhang, X. Hu, S. J. Wei et al., “Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity,” Journal of Neuroinflammation, vol. 5, article no. 21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Lanone, S. Bloc, R. Foresti et al., “Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats,” FASEB Journal, vol. 19, no. 13, pp. 1890–1892, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Santiago, M. C. Hernández-Romero, A. Machado, and J. Cano, “Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not,” European Journal of Pharmacology, vol. 609, no. 1–3, pp. 58–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Nakamichi, M. Saiki, H. Kitani et al., “Suppressive effect of simvastatin on interferon-β-induced expression of CC chemokine ligand 5 in microglia,” Neuroscience Letters, vol. 407, no. 3, pp. 205–210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Cordle and G. Landreth, “3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses,” Journal of Neuroscience, vol. 25, no. 2, pp. 299–307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Yan, Y. Xu, C. Zhu et al., “Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses,” PLoS One, vol. 6, no. 6, article 20945, 2011. View at Publisher · View at Google Scholar
  103. W. Chen, S. Pendyala, V. Natarajan, J. G. N. Garcia, and J. R. Jacobson, “Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition,” American Journal of Physiology, Lung Cellular and Molecular Physiology, vol. 295, no. 4, pp. L575–L583, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Thomas, W. D. Le, and J. Jankovic, “Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease,” Clinical Neuropharmacology, vol. 26, no. 1, pp. 18–23, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. D. C. Wu, V. Jackson-Lewis, M. Vila et al., “Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease,” Journal of Neuroscience, vol. 22, no. 5, pp. 1763–1771, 2002. View at Google Scholar · View at Scopus
  106. S. H. Choi, D. Y. Lee, E. S. Chung, Y. B. Hong, S. U. Kim, and B. K. Jin, “Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo,” Journal of Neurochemistry, vol. 95, no. 6, pp. 1755–1765, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. D. K. Choi, S. Koppula, M. Choi, and K. Suk, “Recent developments in the inhibitors of neuroinflammation and neurodegeneration: inflammatory oxidative enzymes as a drug target,” Expert Opinion on Therapeutic Patents, vol. 20, no. 11, pp. 1531–1546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. P. Page, M. Orchard, L. Fioraso, and B. Mottiromi, “Pyrazolo pyridine derivatives as NADPH oxidase inhibitors,” US 20100048560, 2010.
  109. P. Page, M. Orchard, L. Fioraso, and B. Mottiromi, “Tetrahydroindole derivatives as NADPH oxidase inhibitors,” EP2139472A1, 2010.
  110. J. L. Arbiser, “Use of Imipramine blue and analogs thereof in treating cancers,” US20100160296, 2010.
  111. K. I. Onda, K. Sato, F. Moritomo et al., “Quinolone derivatives,” EP20080834496, 2010.
  112. M. S. Yamamoto and A. U. Saneyoshi, “NADH/NADPH oxidase inhibitors,” JP2009007256, 2009.
  113. S. Przedborski and T. M. Dawson, “The role of nitric oxide in Parkinson's disease,” Methods in Molecular Medicine, vol. 62, pp. 113–136, 2001. View at Google Scholar
  114. J. L. Dinerman, T. M. Dawson, M. J. Schell, A. Snowman, and S. H. Snyder, “Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 10, pp. 4214–4218, 1994. View at Google Scholar · View at Scopus
  115. S. Murphy, “Production of nitric oxide by glial cells: regulation and potential roles in the CNS,” GLIA, vol. 29, no. 1, pp. 1–13, 2000. View at Publisher · View at Google Scholar · View at Scopus
  116. M. T. Heneka and D. L. Feinstein, “Expression and function of inducible nitric oxide synthase in neurons,” Journal of Neuroimmunology, vol. 114, no. 1-2, pp. 8–18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Bal-Price and G. C. Brown, “Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity,” Journal of Neuroscience, vol. 21, no. 17, pp. 6480–6491, 2001. View at Google Scholar · View at Scopus
  118. A. Bal-Price, A. Matthias, and G. C. Brown, “Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production,” Journal of Neurochemistry, vol. 80, no. 1, pp. 73–80, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. Y. Z. Ye, M. Strong, Z. Q. Huang, and J. S. Beckman, “Antibodies that recognize nitrotyrosine,” Methods in Enzymology, vol. 269, pp. 201–209, 1996. View at Google Scholar · View at Scopus
  120. D. Dexter, C. Carter, and F. Agid, “Lipid peroxidation as cause of nigral cell death in Parkinson's disease,” Lancet, vol. 2, no. 8507, pp. 639–640, 1986. View at Google Scholar
  121. L. Broom, L. Marinova-Mutafchieva, M. Sadeghian, J. B. Davis, A. D. Medhurst, and D. T. Dexter, “Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease,” Free Radical Biology and Medicine, vol. 50, no. 5, pp. 633–640, 2011. View at Publisher · View at Google Scholar
  122. C. Gahm, S. Holmin, P. N. Wiklund, L. Brundin, and T. Mathiesen, “Neuroprotection by selective inhibition of inducible nitric oxide synthase after experimental brain contusion,” Journal of Neurotrauma, vol. 23, no. 9, pp. 1343–1354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. M. J. D. Griffiths, M. Messent, R. J. MacAllister, and T. W. Evans, “Aminoguanidine selectively inhibits inducible nitric oxide synthase,” British Journal of Pharmacology, vol. 110, no. 3, pp. 963–968, 1993. View at Google Scholar · View at Scopus
  124. M. Sun, Y. Zhao, Y. Gu, and C. Xu, “Neuroprotective actions of aminoguanidine involve reduced the activation of calpain and caspase-3 in a rat model of stroke,” Neurochemistry International, vol. 56, no. 4, pp. 634–641, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. D. J. Wolff and A. Lubeskie, “Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase,” Archives of Biochemistry and Biophysics, vol. 316, no. 1, pp. 290–301, 1995. View at Publisher · View at Google Scholar
  126. D. Cash, J. S. Beech, R. C. Rayne, P. M. W. Bath, B. S. Meldrum, and S. C. R. Williams, “Neuroprotective effect of aminoguanidine on transient focal ischaemia in the rat brain,” Brain Research, vol. 905, no. 1-2, pp. 91–103, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. J. Lu, S. Moochhala, M. Shirhan et al., “Neuroprotection by aminoguanidine after lateral fluid-percussive brain injury in rats: a combined magnetic resonance imaging, histopathologic and functional study,” Neuropharmacology, vol. 44, no. 2, pp. 253–263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  128. K. M. Cockroft, M. Meistrell, G. A. Zimmerman et al., “Cerebroprotective effects of aminoguanidine in a rodent model of stroke,” Stroke, vol. 27, no. 8, pp. 1393–1398, 1996. View at Google Scholar · View at Scopus
  129. I. D. Stevanović, M. D. Jovanović, M. Čolić et al., “The effect of aminoguanidine, an inducible nitric oxide synthase inhibitor, on ALCL3 toxicity in the rat hippocampus,” Archives of Biological Sciences, vol. 62, no. 4, pp. 981–991, 2010. View at Publisher · View at Google Scholar
  130. Z. J. Zhang, L. C.V. Cheang, M. W. Wang, and S. M.-Y. Lee, “Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish,” International Journal of Molecular Medicine, vol. 27, no. 2, pp. 195–203, 2011. View at Publisher · View at Google Scholar
  131. Y. C. Lin, H. W. Uang, R. J. Lin, I. J. Chen, and Y. C. Lo, “Neuroprotective effects of glyceryl nonivamide against microglia-like cells and 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 323, no. 3, pp. 877–887, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. K. Kotil, U. Kuscuoglu, M. Kirali, H. Uzun, M. Akçetin, and T. Bilge, “Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: a prospective randomized and placebo-control trial,” Journal of Neurosurgery: Spine, vol. 4, no. 5, pp. 392–399, 2006. View at Publisher · View at Google Scholar
  133. S. Condello, M. Curro, N. Ferlazzo, D. Caccamo, J. Satriano, and R. Ientile, “Agmatine effects on mitochondrial membrane potential andNF-kappaB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells,” Journal of Neurochemistry, vol. 116, no. 1, pp. 67–75, 2011. View at Google Scholar
  134. H. Kim, Y. S. Kim, S. Y. Kim, and K. Suk, “The plant flavonoid wogonin suppresses death of activated C6 rat glial cells by inhibiting nitric oxide production,” Neuroscience Letters, vol. 309, no. 1, pp. 67–71, 2001. View at Publisher · View at Google Scholar · View at Scopus
  135. W. Chun, J. L. Hee, P. J. Kong et al., “Synthetic wogonin derivatives suppress lipopolysaccharide-induced nitric oxide production and hydrogen peroxide-induced cytotoxicity,” Archives of Pharmacal Research, vol. 28, no. 2, pp. 216–219, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Hattori, R. Inoue, K. Sase et al., “Preferential inhibition of inducible nitric oxide synthase by ebselen,” European Journal of Pharmacology, Molecular Pharmacology Section, vol. 267, no. 2, pp. R1–R2, 1994. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Moussaoui, M. C. Obinu, N. Daniel, M. Reibaud, V. Blanchard, and A. Imperato, “The antioxidant Ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease,” Experimental Neurology, vol. 166, no. 2, pp. 235–245, 2000. View at Publisher · View at Google Scholar · View at Scopus
  138. T. Dehmer, M. T. Heneka, M. Sastre, J. Dichgans, and J. B. Schulz, “Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation,” Journal of Neurochemistry, vol. 88, no. 2, pp. 494–501, 2004. View at Google Scholar
  139. R. L. Hunter, N. Dragicevic, K. Seifert et al., “Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system,” Journal of Neurochemistry, vol. 100, no. 5, pp. 1375–1386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. B. Xing, M. Liu, and G. Bing, “Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activity,” Journal of Neuroimmunology, vol. 192, no. 1-2, pp. 89–98, 2007. View at Publisher · View at Google Scholar · View at Scopus
  141. Y. C. Chung, S. R. Kim, and B. K. Jin, “Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease,” Journal of Immunology, vol. 185, no. 2, pp. 1230–1237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. S. A. F. Thomas, U. Wolf-Rüdiger, H. Christian, L. Martin, K. B. R. Raimund, and E. Manfrid, “Imidazopyridine derivatives useful as iNOS inhibitors,” US7790710, 2010.
  143. N. T. J. Sharon, R. Sam, L. Guyan, C. Yulin, and M. Jean, “Coumarins as iNOS inhibitors,” US 7538233, 2009.
  144. N. M. O. Tadayoshi, K. Yasuo, W. Koji, and M. Takehito, “Sense Ologonucleotide capable of controlling the expression of iNOS and composition comprising the same,” European Patent EP2031057, 2011.
  145. N. S.-J. K. Heonjoong and K. O. Hyun-Sil, “Pharmaceutical composition,healthfood composition and iNOS inhibitors, containing Theopederin derivatives,” WO/2008/072937A1, 2008.
  146. I. Singh, “Inhibitors of nitric oxide synthase,” US20090192120, 2009.